Weight gain before and after switch from TDF to TAF in a U.S. cohort study

Introduction Although weight gain has been reported with the use of integrase strand transfer inhibitors (InSTI), concurrent use of tenofovir alafenamide (TAF) has been implicated in recent studies. This study examined weight changes in people living with HIV (PLWH) who switched from tenofovir disop...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Journal of the International AIDS Society Ročník 24; číslo 4; s. e25702 - n/a
Hlavní autoři:	Mallon, Patrick WG, Brunet, Laurence, Hsu, Ricky K, Fusco, Jennifer S, Mounzer, Karam C, Prajapati, Girish, Beyer, Andrew P, Wohlfeiler, Michael B, Fusco, Gregory P
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	Switzerland International AIDS Society 01.04.2021 John Wiley & Sons, Inc John Wiley and Sons Inc
Témata:	Acquired immune deficiency syndrome Age AIDS Anticonvulsants Antidepressants Antihypertensives Antiretroviral agents Antiretroviral drugs antiretroviral therapy Body mass index Cohort Cohort analysis Complications and side effects Dementia Diabetes Drug therapy Drugs Electronic health records Health aspects Highly active antiretroviral therapy Histamine HIV HIV infection Human immunodeficiency virus Hyperthyroidism Hypothyroidism integrase strand transfer inhibitor Proteinase inhibitors Psychotropic drugs Sexually transmitted diseases Statistics STD Tenofovir tenofovir alafenamide tenofovir disoproxil fumarate Weight gain United States United States > US integrase strand transfer inhibitor tenofovir alafenamide tenofovir disoproxil fumarate Cohort antiretroviral therapy weight gain
ISSN:	1758-2652, 1758-2652
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!